{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"91.0","value":"99.07"},{"groupId":"OG001","spread":"40.8","value":"48.13"},{"groupId":"OG002","spread":"35.0","value":"59.67"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"5"}],"units":"Participants"}],"title":"Week1 AM dose;n=3,10,5"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"66.0","value":"116.52"},{"groupId":"OG001","spread":"16.6","value":"77.28"},{"groupId":"OG002","spread":"52.6","value":"81.11"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"7"},{"groupId":"OG002","value":"3"}],"units":"Participants"}],"title":"Week1 PM dose;n=3,7,3"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"72.8","value":"71.00"},{"groupId":"OG001","spread":"61.4","value":"54.94"},{"groupId":"OG002","spread":"37.6","value":"112.17"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"7"},{"groupId":"OG002","value":"3"}],"units":"Participants"}],"title":"Week3 AM dose;n=3,7,3"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"65.3","value":"92.00"},{"groupId":"OG001","spread":"29.5","value":"104.52"},{"groupId":"OG002","spread":"41.7","value":"127.34"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"3"}],"units":"Participants"}],"title":"Week3 PM dose;n=3,5,3"}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"5"}],"units":"Participants"}],"description":"Blood samples were collected at indicated time points post ante-meridiem (AM) and post-meridiem (PM) dose for pharmacokinetic analysis of GSK525762.","dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Participants were administered twice daily (BID) oral dose of 20 mg GSK525762.","id":"OG000","title":"Part 1: GSK525762 20 mg BID"},{"description":"Participants were administered twice daily oral dose of 30 mg GSK525762.","id":"OG001","title":"Part 1: GSK525762 30 mg BID"},{"description":"Participants were administered twice daily oral dose of 40 mg GSK525762.","id":"OG002","title":"Part 1: GSK525762 40 mg BID"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"PK Parameter Population. Only those participants with data available at the specified time points were analyzed (indicated by n=X in category titles).","reportingStatus":"POSTED","timeFrame":"pre-dose,0.25,0.5,1,2,4,8,12 hours post-AM dose at Week1Day1 and Week3 Day 4; Week1 Day5(0.5, 3 hours post-AM dose); pre-dose, 0.25,0.5,1,2,4,8,12, 36 hours post-PM dose at Week1Day1 and Week3 Day4","title":"Volume of Distribution of GSK525762-Part 1 BID","type":"SECONDARY","unitOfMeasure":"Liters"}